October 6, 2021
Predicine presented data highlighting the use of PredicineCARE and PredicineATLAS in patients with metastatic breast cancer and early stage bladder cancer. Publications can be found below: (Breast Cancer Abstract) (Bladder Cancer Abstract)    
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)